Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
Conditions
- Resectable Pancreatic Duct Adenocarcinoma
Sponsor
University Hospital, Rouen
Collaborators